AVAGE (tazarotene) by Almirall is form, the carboxylic acid of tazarotene, by deesterification. Approved for retinoid [epc]. First approved in 2000.
Drug data last refreshed 6h ago · AI intelligence enriched 1mo ago
AVAGE is a topical retinoid cream containing tazarotene, approved in 2000 for the treatment of psoriasis and acne. Tazarotene is converted to tazarotenic acid, which binds to retinoic acid receptors (RARα, RARβ, RARγ) with selectivity for RARβ and RARγ to modulate gene expression. It represents a mature, well-established retinoid therapeutic option in dermatology.
Product is in late-stage life cycle with moderate competitive pressure (30/100), indicating potential team consolidation or transition focus.
form, the carboxylic acid of tazarotene, by deesterification. Tazarotenic acid binds to all three members of the retinoic acid receptor (RAR) family: RARα, RARβ, and RARɣ, but shows relative selectivity for RARβ, and RARɣ and may modify gene expression. The clinical significance of these findings…
Retinoid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Traumatic Hemothorax Drainage and Daily Lavage
Chlorhexidine Lavage for Recurrent Urinary Tract Infection
Does Joint Lavage Reduce Intraarticular Inflammation in High-energy Tibial Pilon Fractures?
Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis
Liquid Biopsy for ctDNA in Peritoneal Lavage and Blood in Pancreatic Cancer
Worked on AVAGE at Almirall? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on AVAGE offers stability in a legacy brand but limited growth trajectory due to approaching loss of exclusivity and intense competition. Career progression may be better served by transitioning to growth-stage or newer molecular entities within Almirall's dermatology portfolio.